Friedreich ataxia 1 (FRDA) is an inherited progressive neurological disorder caused by pathogenic variants in the FXN gene, which encodes frataxin, a mitochondrial protein involved in iron-sulfur cluster assembly and regulation of mitochondrial iron homeostasis. According to GeneReviews, FRDA is the most common early-onset inherited ataxia in populations of European, Middle Eastern, South Asian, and North African ancestry, and has not been documented in Southeast Asian, sub-Saharan African, or Native American populations. The condition is inherited in an autosomal recessive manner. GeneReviews reports a prevalence of approximately 0.50 per 100,000 based on molecular diagnosis, with a carrier frequency of approximately 1 in 60 to 1 in 100 in affected populations. FRDA is characterized by progressive cerebellar and sensory ataxia with multi-system involvement, including hypertrophic cardiomyopathy, which represents a major determinant of morbidity and premature mortality.

GeneReviews describes the characteristic presentation of FRDA as progressive ataxia with mean onset between ages 10 and 15 years, with a range from early childhood to the eighth decade. Initial manifestations include impaired balance when walking, followed by progressive upper-limb ataxia and dysarthria. Approximately 75% of individuals have 'typical' FRDA; the remaining approximately 25% present with atypical forms including late-onset FRDA (after age 25), very late-onset FRDA (after age 40), and FRDA with retained reflexes. Sensory neuropathy—manifesting as loss of position sense and vibration sense in the lower limbs—is a defining neurological feature. Pyramidal tract involvement produces lower-extremity weakness and extensor plantar responses. Musculoskeletal complications include scoliosis and pes cavus. Hypertrophic non-obstructive cardiomyopathy develops in the majority of affected individuals and is a primary driver of mortality. Additional manifestations documented by GeneReviews include diabetes mellitus or impaired glucose tolerance in a subset of individuals, hearing loss, and visual impairment from optic atrophy or nystagmus.

FRDA results from severely reduced frataxin expression caused by biallelic pathogenic variants in the FXN gene. According to GeneReviews, the predominant molecular mechanism is homozygous GAA trinucleotide repeat expansion within intron 1 of FXN, which causes transcriptional silencing through heterochromatin formation and epigenetic suppression. Frataxin deficiency leads to abnormal accumulation of intramitochondrial iron, impaired mitochondrial respiratory chain function, and excessive generation of reactive oxygen species, resulting in progressive oxidative damage to neurons and cardiac myocytes. Compound heterozygosity for a GAA expansion on one allele and a conventional pathogenic variant (missense, nonsense, or splice-site) on the other allele accounts for a minority of cases and may be associated with atypical clinical presentations. GeneReviews notes that longer GAA repeat expansions are generally correlated with earlier age of onset and more severe disease.

No formal consensus diagnostic criteria for FRDA have been published, according to GeneReviews. The condition may be suspected in individuals presenting with progressive ataxia, sensory neuropathy, pyramidal signs, musculoskeletal features (scoliosis, pes cavus), and cardiomyopathy—particularly with onset before age 25. Brain MRI demonstrates atrophy of the cervical spinal cord; cerebellar atrophy may also be present in advanced disease. Electrophysiological studies characteristically show absent or markedly reduced sensory nerve action potentials. Echocardiography reveals hypertrophic cardiomyopathy in the majority of affected individuals. Definitive diagnosis relies on molecular genetic testing identifying biallelic pathogenic FXN variants, combining GAA repeat expansion analysis with gene sequencing. GeneReviews notes that GAA repeat length provides genotype-phenotype predictive value: longer repeats correlate with earlier onset and more severe neurological and cardiac involvement.

GeneReviews documents that omaveloxolone is approved in the United States and Europe for individuals with FRDA aged 16 years and older, representing a disease-modifying therapy for this condition. According to GeneReviews, omaveloxolone has been shown to slow the progression of FRDA; the primary side effect noted is alteration in liver function, assessed through hepatic laboratory evaluation as part of clinical management. Supportive care addresses multiple organ systems: physical and occupational therapy to preserve function and mobility, orthopedic management of scoliosis, cardiological assessment and management of hypertrophic cardiomyopathy, endocrinological evaluation for diabetes mellitus, and audiological and ophthalmological follow-up. Among orphan-designated investigational agents, elamipretide and trans-resveratrol carry orphan designation for FRDA but are not approved. Management guidelines have been published and are maintained at frdaguidelines.org, according to GeneReviews.

FRDA follows a progressive course with accumulating neurological and multi-system disability. GeneReviews notes that most individuals become wheelchair-dependent within approximately 10 to 15 years of symptom onset. Cardiomyopathy is the primary determinant of premature mortality, with death from heart failure or arrhythmia occurring in a significant proportion of affected individuals. The approved availability of omaveloxolone represents an advance in disease management, though FRDA remains a life-limiting condition. Longer GAA repeat expansions are generally associated with earlier onset and faster neurological progression. Atypical forms, including late-onset and very late-onset FRDA, may follow slower rates of progression than typical early-onset disease. Diabetes mellitus, when present, contributes additional systemic morbidity.

Research in FRDA spans a broad and active pipeline. GeneReviews documents frataxin-augmentation strategies under clinical investigation, including nomlabofusp (in Phase II trials) and DT-216P (Phase I), which aim to increase frataxin protein levels. Approaches targeting mitochondrial function and oxidative stress include vatiquinone, nicotinamide riboside, and elamipretide, at various stages of clinical evaluation. Gene therapy using viral vectors to deliver a functional FXN gene—including LX2006, an AAV-based vector targeting cardiac tissue—is in Phase I/II investigation. Frataxin-controlled pathway modulation is being explored through leriglitazone and dimethyl fumarate. Active clinical trials in the registry data include gene therapy studies, post-approval observational studies of omaveloxolone, cognitive profiling studies, and digital outcome assessment using AI-based tools. GeneReviews references the FARA drug development pipeline as an ongoing resource for tracking therapeutic advances in this condition.